Abstract
Melatonin, which is secreted principally by the pineal gland at night, affects several cardiovascular conditions including arterial hemodynamics, right ventricle functions, and pulmonary artery functions. Pulmonary hypertension is a hemodynamic and pathophysiological condition defined as an increase of average pulmonary artery pressure exceeding 20 mmHg at rest. In the light of the literature data, as discussed in this study, melatonin and its supplements may play a role in the pathogenesis and treatment of pulmonary hypertension.
Publisher
Kosuyolu Heart Journal, Health Sciences University
Reference23 articles.
1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RM, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618–731. doi: 10.1093/eurheartj/ehac237.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S–24S. doi: 10.1016/jjacc.2004.02.029.
3. Lan NS, Massam BD, Kulkarni SS, Lang CC. Pulmonary arterial hypertension: Pathophysiology and treatment. Diseases 2018;6(2):38. doi: 10.3390/diseases6020038
4. Malhotra S, Sawhney G, Pandhi P. The therapeutic potential of melatonin: A review of the science. MedGenMed 2004;6(2):46. https://www.ncbi.nlm. nih.gov/pmc/articles/PMC1395802/
5. Cai Z, Klein T, Geenen LW, Tu L, Tian S, Van den Bosch AE, et al. Lower plasma melatonin levels predict worse long-term survival in pulmonary arterial hypertension. J Clin Med 2020;9(5):1248. doi: 10.3390/jcm9051248